# PRODIGE 24 (NCT01526135)

> Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

No report yet. It can be ordered.

- Drugs tested: mFOLFIRINOX
- Indication: resected pancreatic adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01526135
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: UNICANCER
- Conditions: Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
- Interventions: mFolfirinox; Gemcitabine
- Enrollment: 493
- Primary outcome: disease-free survival (DFS)

## Indexed commentary on PRODIGE 24 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 69
- YouTube: 5
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=prodige-24-nct01526135

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01526135", "email": "<work email>"}; the inbox owner confirms by the emailed link.